11/21
01:30 pm
regn
Vyriad signs 'huge' deal with Novartis to develop new cancer treatments [Yahoo! Finance]
Low
Report
Vyriad signs 'huge' deal with Novartis to develop new cancer treatments [Yahoo! Finance]
11/19
10:27 am
regn
Here's Why Regeneron Pharmaceuticals (REGN) Declined in Q3 [Yahoo! Finance]
Low
Report
Here's Why Regeneron Pharmaceuticals (REGN) Declined in Q3 [Yahoo! Finance]
11/16
06:05 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/15
08:04 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,150.00 price target on the stock.
Medium
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,150.00 price target on the stock.
11/15
06:03 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
Medium
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
11/15
01:17 am
regn
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) [Yahoo! Finance]
Low
Report
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) [Yahoo! Finance]
11/15
12:59 am
regn
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Low
Report
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
11/14
08:09 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $895.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $895.00 price target on the stock.
11/13
11:16 am
regn
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease [Yahoo! Finance]
Low
Report
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease [Yahoo! Finance]
11/13
07:00 am
regn
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
Low
Report
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
11/12
03:04 pm
regn
Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales [Yahoo! Finance]
Low
Report
Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales [Yahoo! Finance]
11/11
04:05 pm
regn
Regeneron Announces Investor Conference Presentations
Low
Report
Regeneron Announces Investor Conference Presentations
11/10
06:27 am
regn
We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease [Yahoo! Finance]
Low
Report
We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease [Yahoo! Finance]
11/8
11:57 am
regn
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus [Yahoo! Finance]
Low
Report
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus [Yahoo! Finance]
11/8
10:31 am
regn
OncoResponse reports data from Phase I solid tumour treatment trial [Yahoo! Finance]
Low
Report
OncoResponse reports data from Phase I solid tumour treatment trial [Yahoo! Finance]
11/6
09:16 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $1,150.00 to $1,000.00. They now have an "outperform" rating on the stock.
Medium
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $1,150.00 to $1,000.00. They now have an "outperform" rating on the stock.
11/6
04:33 am
regn
Is It Time to Buy October's Worst-Performing Nasdaq Stocks? [Yahoo! Finance]
Low
Report
Is It Time to Buy October's Worst-Performing Nasdaq Stocks? [Yahoo! Finance]
11/6
01:00 am
regn
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
Low
Report
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
11/5
09:31 am
regn
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? [Yahoo! Finance]
Low
Report
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? [Yahoo! Finance]
11/4
11:12 pm
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
11/4
03:00 pm
regn
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
Low
Report
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
11/4
01:24 pm
regn
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
Low
Report
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
11/1
03:44 pm
regn
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
Low
Report
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
11/1
02:52 pm
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Royal Bank of Canada from $1,260.00 to $1,215.00. They now have an "outperform" rating on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Royal Bank of Canada from $1,260.00 to $1,215.00. They now have an "outperform" rating on the stock.
11/1
02:52 pm
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Morgan Stanley from $1,235.00 to $1,184.00. They now have an "overweight" rating on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Morgan Stanley from $1,235.00 to $1,184.00. They now have an "overweight" rating on the stock.